Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43026 (
lipopolysaccharide
)
62,215
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
RAW 264.7 macrophages express nonmuscle myosin heavy chain II-A as the only significant nonmuscle myosin heavy chain isoform, with expression of nonmuscle myosin heavy chain II-B and II-C low or absent. Treatment of the cells with sodium butyrate, an inhibitor of histone deacetylase, led to the dose-dependent induction of
nonmuscle myosin heavy chain II-C
. Trichostatin A, another inhibitor of histone deacetylase, also induced
nonmuscle myosin heavy chain II-C
. Induction of
nonmuscle myosin heavy chain II-C
in response to these histone deacetylase inhibitors was attenuated by mithramycin, an inhibitor of Sp1 binding to GC-rich DNA sequences. Bacterial
lipopolysaccharide
alone had no effect on basal
nonmuscle myosin heavy chain II-C
expression, but attenuated butyrate-mediated induction of
nonmuscle myosin heavy chain II-C
. The effects of
lipopolysaccharide
were mimicked by the nitric oxide donors sodium nitroprusside and spermine NONOate, suggesting a role for nitric oxide in the
lipopolysaccharide
-mediated down-regulation of
nonmuscle myosin heavy chain II-C
induction. This was supported by experiments with the inducible nitric-oxide synthase inhibitor 1400W, which partially blocked the
lipopolysaccharide
-mediated attenuation of nonmuscle myosin heavy chain induction. 8-Bromo-cGMP had no effect on nonmuscle myosin heavy chain induction, consistent with a cGMP-independent mechanism for nitric oxide-mediated inhibition of
nonmuscle myosin heavy chain II-C
induction.
...
PMID:Induction of nonmuscle myosin heavy chain II-C by butyrate in RAW 264.7 mouse macrophages. 1259 34
